Trial Profile
Single Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Nov 2015
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2013 New trial record